CAR T-Cell Therapy

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

Community oncology practices can deliver chimeric antigen receptor (CAR) T-cell therapy safely, effectively, and in a sustained manner.

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with older age and frailty.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

Phase 2 data show one-time liso-cel CAR T delivers 95% responses in hard-to-treat marginal zone lymphoma, with low severe CRS and neurotoxicity.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

Macrophage cell therapy may skip lymphodepleting chemo, reducing toxicity and secondary cancer risk for heavily pretreated, frail patients.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

New Uniphar deal widens European managed-access to Lymphir for relapsed CTCL, spotlighting targeted immunotherapy and manageable early-cycle risks.

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant, thus closing the access gap.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.